SGN-CD47M / Pfizer - LARVOL DELTA

Preclinical development of SGN-CD47M: Protease-activated antibody technology enables selective tumor targeting of the innate immune checkpoint receptor CD47. (PubMed, Mol Cancer Ther) - "SGN-CD47M also displays preferential activation in the tumor microenvironment that leads to robust single-agent antitumor activity. For these reasons, SGN-CD47M may have enhanced antitumor activity and improved tolerability relative to existing therapies that target the CD47-SIRPα interaction."

Journal • Preclinical • Hematological Disorders • Oncology • CD47 • SIRPA

A Safety Study of SGN-CD47M in Patients With Solid Tumors (clinicaltrials.gov) - P1; N=16; Terminated; Sponsor: Seattle Genetics, Inc.; N=205 ➔ 16; Trial completion date: Sep 2022 ➔ Sep 2020; Recruiting ➔ Terminated; Trial primary completion date: Mar 2022 ➔ Sep 2020; Sponsor decision based on portfolio prioritization

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Hepatology • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

A Safety Study of SGN-CD47M in Patients With Solid Tumors (clinicaltrials.gov) - P1; N=205; Recruiting; Sponsor: Seattle Genetics, Inc.; Trial completion date: Mar 2022 ➔ Sep 2022; Trial primary completion date: Sep 2021 ➔ Mar 2022

Clinical • Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Head and Neck Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thoracic Cancer

A Safety Study of SGN-CD47M in Patients With Solid Tumors (clinicaltrials.gov) - P1; N=205; Recruiting; Sponsor: Seattle Genetics, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open